Healthcare | April 20, 2026
Energy drinks emerging as hidden driver of liver damage in India’s youth, warn experts
Medical experts point to a growing body of research linking energy drinks to liver injury
Medical experts point to a growing body of research linking energy drinks to liver injury
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Subscribe To Our Newsletter & Stay Updated
